Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Milestone Pharmaceuticals Announces Proposed Public Offering
-
TD Cowen Downgrades Milestone Pharmaceuticals (MIST) to Hold
-
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
-
TD Cowen Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
-
TD Cowen Reiterates Buy Rating on Milestone Pharmaceuticals (MIST)
-
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
-
Milestone Pharmaceuticals (MIST) Announces $125M Financing with RTW Investments
-
Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT
-
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
-
Milestone Pharmaceuticals (MIST) PT Raised to $17 at Cowen Following Data
-
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
-
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
-
Milestone Pharmaceuticals (MIST) PT Doubled to $12 at Cowen
-
Pappas Capital Expands Leadership Team With Appointments Of Kyle Rasbach To Managing Partner And Matthew Boyer To Chief Financial Officer
-
Cowen Starts Milestone Pharmaceuticals (MIST) at Outperform
-
Milestone Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering
-
Milestone Pharmaceuticals Announces Closing of Initial Public Offering
-
Milestone Pharmaceuticals (MIST) IPO Opens 4% Higher
-
Milestone Pharmaceuticals Inc. (MIST) Prices Upsized 5.5M Share IPO at $15/Sh
-
Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering

